SEC Form DFiling only, no announcement found
Voxcell BioInnovation, based in Victoria, A1, reported $2,200,676 sold in a private offering of Simple Agreements for Future Equity (SAFEs) and the Equity or Security to be acquired upon conversion of the SAFEs, with the first sale on August 19, 2026, in a Form D filed with the SEC on September 1, 2026. The filing says 31 investors have already invested.
Legal name on the filing: Voxcell BioInnovation Inc..
| Amount sold | $2,200,676Basis: Form D total amount sold, as of the filing of September 1, 2026. Not the announced round size. |
|---|---|
| Total offering | $2,200,676The most the company may sell under this offering. Not money raised. |
| Remaining to be sold | $0 |
| Securities offered | Other (Simple Agreements for Future Equity (SAFEs) and the Equity or Security to be acquired upon conversion of the SAFEs) |
| Exemption claimed | Rule 506(b) |
| Date of first sale | August 19, 2026 |
| Investors already invested | 31 |
| Non-accredited investors | None |
| Minimum investment accepted | $0 |
| Part of a merger or acquisition | No |
| Industry group | Biotechnology |
| Principal place of business | Victoria, A1 |
| Jurisdiction of incorporation | BRITISH COLUMBIA, CANADA |
| Entity type | Corporation |
| Year of incorporation | over five years ago |
| Revenue range | Decline to Disclose |
| SEC CIK | 2041826 |
Round name, valuation, lead investor and participants are not on a Form D, so they are not shown. They appear here only when a press or company announcement is matched to this deal.
| Name, as filed | Relationship | VC Beast profile |
|---|---|---|
| Karolina Papera Valente | Executive Officer, Director | None linked |
| Thomas Neumann | Director | None linked |
| Marie-Helene Raigneau | Director | None linked |
| Jessica Miller | Director | None linked |
| Mark Miller | Director | None linked |
Form D lists the company's executive officers, directors and promoters. A director is often an investor's board representative, but the filing does not say who invested.
| Filed | Form | Amount sold | Total offering |
|---|---|---|---|
| Sep 1, 2026 | D (original) | $2,200,676 | $2,200,676 |
The latest filing states the current amount sold; an amendment replaces the figure before it.
From the issuer's EDGAR filing history. Amounts are shown for filings in our warehouse, which holds operating-company filings from July 16, 2026.
Filing only, no announcement found. The only source for this deal is the company's own SEC filing, made under penalty of law. When a press or company announcement is matched to it, it is cited here with the round name it gives.
Amount sold is the filing's total amount sold; total offering is its authorized maximum. This page was built from filings received through September 29, 2026. Report an error on the corrections page.
Cite this deal
VC Beast, "Voxcell BioInnovation: SEC Form D deal record", https://vcbeast.com/deals/voxcell-bioinnovation-form-d-2026-08-19. Source: SEC EDGAR, accession 0002041826-26-000003.